Year: 2020

Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments

Ovarian carcinoma claims the lives of more than 14,000 American women every year. It is often detected at late stages and the standard treatment based on surgery and chemotherapy have met with very limited success during the past 40 years…

Read on

Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer

More than 22,000 women develop ovarian cancer each year in the United States. Despite substantial improvements in surgery and chemotherapy, the disease still proves lethal in 70% of cases…

Read on

Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer

Cancers typically develop from a single cell that proliferates and expands in space and time. Modeling the process of clonal evolution in cancer may enable the prediction of progression and response to therapy…

Read on

Precision Medicine in Ovarian Cancer: Using Single Cell Analysis

Despite progress in the understanding of tumor biology, clinical trials designed using specialized new therapies against specific biologic and genetic changes in patient’s tumors commonly fail…

Read on

The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells

Cancer cells display uncontrollable growth and high genetic instability…

Read on

Chromatin Remodeling and Immunotherapy in Ovarian Cancer

Cancer immunotherapies such as drugs targeting the immune inhibitory molecules known as PD-1 and PD-L1 have shown benefit across a number of cancers. Unfortunately, in ovarian cancer, only a small fraction of patients responds to such treatments…

Read on

Tumor-Derived Extracellular Vesicle in Ovarian Cancer

If ovarian cancer takes decades to develop, why are we still unable to detect the disease at an early stage when surgery is curative? Only recently have scientist demonstrated that many of the most common and deadly ovarian cancers actually do not…

Read on

Profiling Co-Evolution of Ovarian Cancer and its Immune Microenvironment

Women with high grade serous ovarian cancer HGSOC represent 70% of all ovarian cancers and suffer high morbidities and poor response to standard of care treatment. The five-year survival rate after diagnosis is <50%…

Read on

Interplay Between Ovarian Cancer Stem Cells and the Tumor Microenvironment

The aim of this project is to find new treatments for the most common type of ovarian cancer, high-grade serous ovarian cancer…

Read on

Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma

Cancer surgery and chemotherapy can be life-saving, however for some cancers, they may also cause the development of future metastases…

Read on